Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A combination study of BHV-1510 with Libtayo (cemiplimab-rwlc)

Next Previous
Trial Profile

A combination study of BHV-1510 with Libtayo (cemiplimab-rwlc)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BHV 1510 (Primary) ; Cemiplimab (Primary)
  • Indications Carcinoma; Solid tumours
  • Focus Therapeutic Use

Most Recent Events

  • 03 Mar 2025 According to a Biohaven Pharmaceuticals media release, the company expect an interim Phase 1 data with BHV-1510 and dose optimization as monotherapy and combination therapy with Libtayo in epithelial tumors in 2025.
  • 31 May 2024 New trial record
  • 29 May 2024 According to a Biohaven Pharmaceuticals media release, company entered into a clinical supply agreement with Regeneron to study the combination of BHV-1510 with Regeneron's anti-PD1 Libtayo (cemiplimab-rwlc) in the clinical study

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top